Notice of Award of a Sole Source Cooperative Agreement to Fund Secretaria Ejecutiva del Consejo de Ministros de Salud de Centroamerica y Republica Dominicana (SE-COMISCA), 104162-104163 [2024-30223]

Download as PDF 104162 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2024–30480 Filed 12–19–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Safety and Occupational Health Study Section; Notice of Solicitation of Nominations for Appointment; Correction Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice; correction. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Safety and Occupational Health Study Section (SOHSS). SOHSS consists of 20 experts in fields associated with occupational medicine and nursing, industrial hygiene, occupational safety and engineering, toxicology, chemistry, safety and health education, ergonomics, epidemiology, economic science, psychology, pulmonary pathology/physiology, and social science. DATES: Nominations for membership on SOHSS must be received no later than January 31, 2025. Packages received after this time will not be considered for the current membership cycle. ADDRESSES: All nominations should be mailed to Dr. Michael Goldcamp, 1095 Willowdale Road, Morgantown, West Virginia 26505 or emailed to MGoldcamp@cdc.gov. FOR FURTHER INFORMATION CONTACT: Michael Goldcamp, Ph.D., Scientific Review Officer, Office of Extramural Programs, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone: (304) 285–5951; email: MGoldcamp@cdc.gov. SUPPLEMENTARY INFORMATION: ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: Correction Notice is hereby given of a correction in the SUPPLEMENTARY INFORMATION section of the original solicitation of nominations notice, which was VerDate Sep<11>2014 20:12 Dec 19, 2024 Jkt 265001 published in the Federal Register on December 2, 2024, 89 FR 95214. The notice is being amended to remove the sentence concerning Special Government Employees, since members of the Safety and Occupational Health Study Section serve as Peer Review Consultants. The SUPPLEMENTARY INFORMATION section should read as follows: SUPPLEMENTARY INFORMATION: Nominations are sought for individuals who have the expertise and qualifications necessary to contribute to the accomplishment of the objectives of the Safety and Occupational Health Study Section (SOHSS). Nominees will be selected based on expertise in the fields of occupational medicine and nursing, industrial hygiene, occupational safety and engineering, toxicology, chemistry, safety and health education, ergonomics, epidemiology, economic science, psychology, pulmonary pathology/physiology, and social science. Members may be invited to serve up to four-year terms. Selection of members is based on candidates’ qualifications to contribute to the accomplishment of SOHSS objectives (https://www.cdc.gov/faca/committees/ sohss.html). Department of Health and Human Services (HHS) policy stipulates that committee membership be balanced in terms of points of view represented and the committee’s function. Appointments shall be made without discrimination on the basis of age, race, ethnicity, gender, sexual orientation, gender identity, HIV status, disability, and cultural, religious, or socioeconomic status. Nominees must be U.S. citizens and cannot be full-time employees of the U.S. Government. Current participation on Federal workgroups or prior experience serving on a Federal advisory committee does not disqualify a candidate; however, HHS policy is to avoid excessive individual service on advisory committees and multiple committee memberships. The Centers for Disease Control and Prevention (CDC) reviews potential candidates for SOHSS membership each year and provides a slate of nominees for consideration to the Secretary of HHS for final selection. HHS notifies selected candidates of their appointment near the start of the term in October 2025, or as soon as the HHS selection process is completed. Note that the need for different expertise varies from year to year and a candidate who is not selected in one year may be reconsidered in a subsequent year. Candidates should submit the following items: PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 D Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address). D At least one letter of recommendation from person(s) not employed by HHS. Candidates may submit letter(s) from current HHS employees if they wish, but at least one letter must be submitted by a person not employed by an HHS agency (e.g., CDC, National Institutes of Health, Food and Drug Administration). Nominations may be submitted by the candidate or by the person/organization recommending the candidate. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–30410 Filed 12–19–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Award of a Sole Source Cooperative Agreement to Fund Secretaria Ejecutiva del Consejo de Ministros de Salud de Centroamerica y Republica Dominicana (SE–COMISCA) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $5,000,000, with an expected total funding of approximately $25,000,000 over a 5-year period, to SE–COMISCA. The award will build upon previous efforts by the CDC in collaboration with Ministries of Health of Central America and the Dominican Republic (SE–COMISCA). DATES: The period for this award will be September 30, 2025 through September 29, 2030. SUMMARY: E:\FR\FM\20DEN1.SGM 20DEN1 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices FOR FURTHER INFORMATION CONTACT: Broderick Yoerg, Division of Global Health Protection, Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd., Atlanta, GA 30329, email: DGHPNOFOs@ cdc.gov, telephone: 404–234–0666. The sole source award will target increased capacity at the national and subnational level to implement and achieve outbreak/epidemic/pandemic control in line with US Government (USG) and CDC strategy. This collaborative effort has led to significant progress in various areas under the Global Health Strategic Framework, including One Health workshops in multiple countries to prioritize zoonotic diseases and the development of a joint action plan for Central America. SE–COMISCA is the only entity that can carry out this work, as it will improve outbreak control capacity, better integration between health systems, and increased equity in healthcare access for all populations, especially those historically marginalized. SUPPLEMENTARY INFORMATION: Summary of the Award ddrumheller on DSK120RN23PROD with NOTICES1 Recipient: SE–COMISCA Purpose of the Award: The purpose of this award is to support Global Health Security goals in Central America and the Dominican Republic by collaborating with MOH and other partners. Efforts will focus on reaching underserved populations, prioritizing equity to build resilient health systems that protect vulnerable groups. Amount of Award: $5,000,000 in Federal Fiscal Year (FFY) 2025 funds, with a total estimated $25,000,000 for the 5-year period of performance, subject to availability of funds. Authority: This program is authorized under section 307 of the Public Health Service Act [42 U.S.C. 24l) and Section 301(a)[42 U.S.C. 24l(a) of the Public Health Service Act. Period of Performance: September 30, 2025 through September 29, 2030. Dated: December 10, 2024. Terrance Perry, Acting Director, Office of Grants Services, Centers for Disease Control and Prevention. [FR Doc. 2024–30223 Filed 12–19–24; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 20:12 Dec 19, 2024 Jkt 265001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC–2020–0046; NIOSH–233– C] Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: General notice. AGENCY: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the publication of the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024, as well as final reevaluation determinations removing the drugs liraglutide and pertuzumab from the NIOSH List of Hazardous Drugs in Healthcare Settings. DATES: The documents announced in this notice are available on December 20, 2024. ADDRESSES: The documents announced in this notice are available in the docket at www.regulations.gov and through the NIOSH Hazardous Drug Exposures in Healthcare website at https:// www.cdc.gov/niosh/healthcare/ hazardous-drugs/. FOR FURTHER INFORMATION CONTACT: Jerald Ovesen, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS–C15, Cincinnati, OH 45226, telephone: (513)533–8472 (not a toll-free number), email: jovesen@cdc.gov. SUPPLEMENTARY INFORMATION: This notice is organized as follows: SUMMARY: I. Public Participation II. Background III. NIOSH Response to Public Comment in the May 2020 Federal Register Notice and Request for Comment A. General Characteristics of the List 1. Timing of the List 2. Drugs That Did Not Meet the NIOSH Hazardous Drug Criteria B. General Drug Descriptors 1. Unique Identifiers 2. Use of AHFS Classifications 3. Use of AHFS Code for Hormone Drug Classification 4. Monoclonal Antibodies as a Class of Drugs 5. Progestins 6. Additional Information Requested C. General Reorganization of the List 1. Content of Tables PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 104163 2. DailyMed and DrugBank Links D. Drugs Not on the Draft 2020 List 1. Drugs Proposed in February 2018 and Not Added to the Draft 2020 List 2. Bacillus Calmette-Guerin (BCG) 3. Botulinum Toxins E. Requests for Specific Drugs To Be Removed From the List 1. Blinatumomab 2. Carfilzomib 3. Eslicarbazepine, Lomitapide, Mifepristone 4. Hazardous Drugs Listed for Reproductive and Developmental Effects: Cabergoline, Clonazepam, Fluconazole, Plerixafor, Riociguat, and Ziprasidone 5. Icatibant 6. Leuprolide 7. Olaparib and Teriflunomide 8. Oxytocin and Other Oxytocic Drugs 9. Paroxetine 10. Spironolactone 11. Topiramate 12. Ulipristal 13. Vigabatrin F. Placement of Specific Drugs Within the List 1. Carfilzomib 2. Dasatinib and Imatinib 3. Eribulin 4. Exenatide 5. Ganciclovir and Valganciclovir 6. Hormonal Agents: Goserelin, Degarelix, Leuprolide, Estrogens, and Progesterone 7. Mycophenolate Mofetil and Mycophenolic Acid 8. Sirolimus and Other Related mTOR Targeting Drugs 9. Thalidomide, Lenalidomide, and Pomalidomide 10. Vandetanib G. Specific Drugs Classification/ Identification 1. Triptorelin 2. Ziv-Aflibercept, Ado-Trastuzumab Emtansine, Fam-Trastuzumab Deruxtecan H. Suggested Copyedits IV. NIOSH Response to Public Comment and Peer Review in the January 2024 Federal Register Notice and Request for Comment on Proposed Removal of Liraglutide and Pertuzumab From the List A. Public Comment 1. General Comments 2. Liraglutide 3. Pertuzumab a. Is this an appropriate method for evaluating the potential for exposure to pertuzumab? b. Is oligohydramnios the best health effect to evaluate? If not, what other health effect(s) should be evaluated and why? c. Is a needlestick injury the only reasonable route of exposure for healthcare workers? d. Are the assumptions about the amount of exposure to pertuzumab in a healthcare setting reasonable? i. Inhalation ii. Percutaneous Exposure iii. Oral exposure e. What alternatives could be considered to this approach for monoclonal antibodies to characterize the potential hazard to workers? E:\FR\FM\20DEN1.SGM 20DEN1

Agencies

[Federal Register Volume 89, Number 245 (Friday, December 20, 2024)]
[Notices]
[Pages 104162-104163]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-30223]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Award of a Sole Source Cooperative Agreement to Fund 
Secretaria Ejecutiva del Consejo de Ministros de Salud de Centroamerica 
y Republica Dominicana (SE-COMISCA)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), located 
within the Department of Health and Human Services (HHS), announces the 
award of approximately $5,000,000, with an expected total funding of 
approximately $25,000,000 over a 5-year period, to SE-COMISCA. The 
award will build upon previous efforts by the CDC in collaboration with 
Ministries of Health of Central America and the Dominican Republic (SE-
COMISCA).

DATES: The period for this award will be September 30, 2025 through 
September 29, 2030.

[[Page 104163]]


FOR FURTHER INFORMATION CONTACT: Broderick Yoerg, Division of Global 
Health Protection, Global Health Center, Centers for Disease Control 
and Prevention, 1600 Clifton Rd., Atlanta, GA 30329, email: 
[email protected], telephone: 404-234-0666.

SUPPLEMENTARY INFORMATION: The sole source award will target increased 
capacity at the national and subnational level to implement and achieve 
outbreak/epidemic/pandemic control in line with US Government (USG) and 
CDC strategy. This collaborative effort has led to significant progress 
in various areas under the Global Health Strategic Framework, including 
One Health workshops in multiple countries to prioritize zoonotic 
diseases and the development of a joint action plan for Central 
America.
    SE-COMISCA is the only entity that can carry out this work, as it 
will improve outbreak control capacity, better integration between 
health systems, and increased equity in healthcare access for all 
populations, especially those historically marginalized.

Summary of the Award

    Recipient: SE-COMISCA
    Purpose of the Award: The purpose of this award is to support 
Global Health Security goals in Central America and the Dominican 
Republic by collaborating with MOH and other partners. Efforts will 
focus on reaching underserved populations, prioritizing equity to build 
resilient health systems that protect vulnerable groups.
    Amount of Award: $5,000,000 in Federal Fiscal Year (FFY) 2025 
funds, with a total estimated $25,000,000 for the 5-year period of 
performance, subject to availability of funds.
    Authority: This program is authorized under section 307 of the 
Public Health Service Act [42 U.S.C. 24l) and Section 301(a)[42 U.S.C. 
24l(a) of the Public Health Service Act.
    Period of Performance: September 30, 2025 through September 29, 
2030.

    Dated: December 10, 2024.
Terrance Perry,
Acting Director, Office of Grants Services, Centers for Disease Control 
and Prevention.
[FR Doc. 2024-30223 Filed 12-19-24; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.